US judge allows hospital suit alleging Lundbeck heart drug monopoly toproceed
This article was originally published in Scrip
Executive Summary
A federal judge has refused to dismiss a putative class action brought by a US hospital system against Lundbeck, alleging that Lundbeck/Ovation Pharmaceuticals put in place an anticompetitive arrangement which allowed it to profit by maintaining artificially high prices for the only two drugs approved to treat patent ductus arteriosus (PDA) in premature babies.